Latvian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
World Journal of Clinical Cases 2020-May

Serotonin transporter and cholecystokinin in diarrhea-predominant irritable bowel syndrome: Associations with abdominal pain, visceral hypersensitivity and psychological performance

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
Saite tiek saglabāta starpliktuvē
Geng Qin
Yu Zhang
Shu-Kun Yao

Atslēgvārdi

Abstrakts

Background: Visceral hypersensitivity and psychological performance are the main pathophysiological mechanisms of irritable bowel syndrome (IBS). Previous studies have found that cholecystokinin (CCK) can enhance colon movement and that serotonin transporter (SERT) is a transmembrane transport protein with high affinity for 5-hydroxytryptamine, which can rapidly reuptake 5-hydroxytryptamine and then regulate its action time and intensity. We speculate that SERT and CCK might play a role in the pathogenesis of diarrhea-predominant IBS (IBS-D) by affecting visceral sensitivity and the brain-gut axis.

Aim: To determine SERT and CCK levels in IBS-D patients diagnosed using Rome IV criteria and to analyze their associations with abdominal pain, visceral hypersensitivity and psychological performance.

Methods: This study collected data from 40 patients with IBS-D at the China-Japan Friendship Hospital from September 2017 to April 2018 and 18 healthy controls. The severity of abdominal pain, visceral sensitivity and psychological performance were evaluated in IBS-D patients and healthy controls, the levels of SERT and CCK in plasma and colonic mucosa were evaluated, and the correlations between them were analyzed.

Results: There were significant differences in the initial sensation threshold (31.00 ± 8.41 mL vs 52.22 ± 8.09 mL, P < 0.001), defecating sensation threshold (51.75 ± 13.57 mL vs 89.44 ± 8.73 mL, P < 0.001) and maximum tolerable threshold (97.25 ± 23.64 mL vs 171.11 ± 20.83 mL, P < 0.001) between the two groups. IBS-D patients had more severe anxiety (7.78 ± 2.62 vs 2.89 ± 1.02, P < 0.001) and depressive (6.38 ± 2.43 vs 2.06 ± 0.73, P < 0.001) symptoms than healthy controls. Significant differences were also found in mucosal CCK (2.29 ± 0.30 vs 1.66 ± 0.17, P < 0.001) and SERT (1.90 ± 0.51 vs 3.03 ± 0.23, P < 0.001) between the two groups. There was a significant positive correlation between pain scores and mucosal CCK (r = 0.96, 0.93, 0.94, P < 0.001). Significant negative correlations between anxiety (r = -0.98; P < 0.001), depression (r = -0.99; P < 0.001), pain evaluation (r = -0.96, -0.93, -0.95, P < 0.001) and mucosal SERT were observed.

Conclusion: IBS-D patients had psychosomatic disorders and visceral hypersensitivity. SERT and CCK might be involved in the pathogenesis of IBS-D by regulating the brain-gut axis and affecting visceral sensitivity. This provides a new potential method for identifying a more specific and effective therapeutic target.

Keywords: Abdominal pain; Cholecystokinin; Irritable bowel syndrome; Psychological performance; Serotonin transporter; Visceral hypersensitivity.

Pievienojieties mūsu
facebook lapai

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne

  • Darbojas 55 valodās
  • Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
  • Garšaugu atpazīšana pēc attēla
  • Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
  • Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
  • Meklēt ārstniecības augus pēc to iedarbības
  • Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem

Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem

Google Play badgeApp Store badge